You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

RRMS

Showing 1 - 25 of 434
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Assess New Participant's Perspectives Beyond Clinical Efficacy

Not yet recruiting
  • Multiple Sclerosis, Relapsing-Remitting
    • (no location specified)
    Nov 7, 2023

    Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

    Not yet recruiting
    • Relapsing-remitting Multiple Sclerosis (RRMS)
      • (no location specified)
      Apr 11, 2023

      Multiple Sclerosis Trial (Natalizumab)

      Not yet recruiting
      • Multiple Sclerosis
      • (no location specified)
      Jun 21, 2023

      Describe Switching FromFirst- or Second-line Disease Modifying

      Not yet recruiting
      • Multiple Sclerosis, Relapsing-Remitting
        • (no location specified)
        Dec 12, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Washington (NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS)

        Completed
        • Multiple Sclerosis, Relapsing-Remitting
        • NeuroQuant
        • +3 more
        • Washington, District of Columbia
          The George Washignton University
        Jan 4, 2023

        Multiple Sclerosis, Neurogenic Bladder Trial in Lubbock (vaginal estriol)

        Completed
        Has Results
        • Multiple Sclerosis
        • Neurogenic Bladder
        • vaginal estriol
        • Lubbock, Texas
          Texas Tech University Health Sciences Center
        Aug 25, 2022

        Multiple Sclerosis Trial in Shreveport (Interferon beta 1a, oral doxycycline)

        Completed
        Has Results
        • Multiple Sclerosis
        • Interferon beta 1a, oral doxycycline
        • Shreveport, Louisiana
          LSU Health Sciences Center Shreveport
        Oct 11, 2022

        Lesion Load and Location in Relation to Cognition, Fatigue and

        Completed
        • Relapsing Remitting Multiple Sclerosis
        • VolBrain, a fully automated platform to generate the volumetric data (lesion count, volume and location as well as different atrophy measures)
        • Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
        • Assiut, Egypt
          Eman Khedr
        Oct 27, 2022

        Mechanistic Studies of Teriflunomide in RRMS

        Active, not recruiting
        • Relapsing Remitting Multiple Sclerosis
        • Ann Arbor, Michigan
          University of Michigan
        Jul 27, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Yvoir (Multiparametric assessment)

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Multiparametric assessment
        • Yvoir, Namur, Belgium
          CHU UCL Namur site Godinne
        Aug 19, 2022

        Relapsing-remitting Multiple Sclerosis (RRMS) Trial in New York (BeCare application)

        Recruiting
        • Relapsing-remitting Multiple Sclerosis (RRMS)
        • BeCare application
        • New York, New York
          Mount Sinai Hospital
        Dec 13, 2021

        Relapsing Remitting Multiple Sclerosis Trial (Laquinimod, Avonex®)

        Withdrawn
        • Relapsing Remitting Multiple Sclerosis
        • (no location specified)
        Nov 5, 2021

        Assess Resource Utilization and Quality of Life of RRMS Treated

        Completed
        • RRMS
        • Dimethyl Fumarate (DMF)
        • Thessaloniki, Greece
          University General Hospital AHEPA (B')
        Jul 27, 2021

        Multiple Sclerosis, Relapsing-Remitting Trial in France (drug, procedure, behavioral)

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Nebido® Testosterone Undecanoate 1000 Mg/4 mL Solution for Injection
        • +4 more
        • Besançon, France
        • +3 more
        Oct 18, 2021

        Multiple Sclerosis Trial in Ashkelon, Haifa, Tel Aviv (GA Depot 80 mg, GA Depot 40 mg)

        Active, not recruiting
        • Multiple Sclerosis
        • GA Depot 80 mg
        • GA Depot 40 mg
        • Ashkelon, Israel
        • +2 more
        Aug 9, 2021

        Multiple Sclerosis, Relapsing-Remitting Trial in Bordeaux (Clinical assessment, Ecological evaluation, Neuropsychological

        Active, not recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Clinical assessment
        • +4 more
        • Bordeaux, France
          CHU de Bordeaux - Service de neurologie
        Feb 2, 2022

        Multiple Sclerosis, Relapsing-Remitting Trial in Kocaeli (EK-12, INF beta-1a)

        Recruiting
        • Multiple Sclerosis, Relapsing-Remitting
        • Kocaeli, Turkey
          Kocaeli University, Faculty of Medicine, Department of Neurology
        Jul 23, 2021

        Multiple Sclerosis Trial in Worldwide (Alemtuzumab GZ402673, Glatiramer acetate, Beta-Interferon)

        Active, not recruiting
        Has Results
        • Multiple Sclerosis
        • Alemtuzumab GZ402673
        • +11 more
        • Wien, Austria
        • +20 more
        Jun 16, 2022

        Relapsing Remitting Multiple Sclerosis (RRMS) Trial in Tehran (Pegylated interferon beta-1a, Interferon Beta-1A Prefilled

        Active, not recruiting
        • Relapsing Remitting Multiple Sclerosis (RRMS)
        • Pegylated interferon beta-1a
        • Interferon Beta-1A Prefilled Syringe
        • Tehran, Iran, Islamic Republic of
          Sina Hospital
        Feb 5, 2022

        Data to Evaluate Impact of Ocrelizumab Used in Routine Care in

        Recruiting
        • Multiple Sclerosis
          • Strasbourg, France
            Hautepierre Clinical Investigation Center - Strasbourg Universit
          Apr 8, 2021

          Quality of Life in Clinical Practice in Germany for

          Recruiting
          • Multiple Sclerosis, Relapsing-Remitting
            • Dresden, Saxony, Germany
              Universitätsklinikum Dresden, MS Ambulanz
            Apr 12, 2022

            Imaging Interplay Between Axonal Damage and Repair in Multiple

            Recruiting
            • Multiple Sclerosis (MS)
            • +3 more
            • MRI
            • +2 more
            • Basel, Switzerland
              University Hospital Basel, Department of Neurology
            Dec 15, 2021

            Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)

            Recruiting
            • Relapse Remitting Multiple Sclerosis
            • Chandler, Arizona
            • +16 more
            Jan 13, 2023

            Relapsing Remitting Multiple Sclerosis Trial in Worldwide (Pleneva TM BGC20-0134, Placebo)

            Terminated
            • Relapsing Remitting Multiple Sclerosis
            • Pleneva TM BGC20-0134
            • Placebo
            • Gent, Belgium
            • +34 more
            Jun 2, 2022

            Neurodegeneration in Multiple Sclerosis -Preclinical Study

            Not yet recruiting
            • Relapsing-Remitting Multiple Sclerosis (RRMS)
            • +2 more
            • Peripheral blood withdrawal
            • Pozzilli, Isernia, Italy
            • +2 more
            Feb 15, 2022